IMIG 2014: Mesothelioma: Cancer stem cells by defactinib, a novel inhibitor of FAK

Paul Baas summarizes evidence from studies showing specific targeting of cancer stem cells by defactinib, a novel inhibitor of FAK.

Click here to watch Paul Baas

Related articles

• Novel cancer vaccine holds promise against ovarian cancer, mesothelioma (workers-compensation.blogspot.com)
• Curcumin, special peptides boost cancer-blocking PIAS3 to neutralize cancer-activating STAT3 in mesothelioma (workers-compensation.blogspot.com)
• Overlooked Lymph Nodes in Rib Cage Have Prognostic Power for Mesothelioma Patients (workers-compensation.blogspot.com)
• Malignant Mesothelioma Treatment (PDQ ) (workers-compensation.blogspot.com)
• Petition Aims to Build First Federally Funded Mesothelioma Program (workers-compensation.blogspot.com)
• Consequences of asbestos: New laboratory installed for research into pleural cancer (workers-compensation.blogspot.com)
• Rising caseload, fewer Labor Department judges triggers painful mix for suffering laborers (workers-compensation.blogspot.com)
• Cancer victims win $190 million in asbestos case (workers-compensation.blogspot.com)